Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis.

Thu Minh TruongGaurav N PathakAmit SingalViktoriia TarantoBabar K Rao

Published in: The Annals of pharmacotherapy (2023)

Deucravacitinib shows a consistent efficacy and safety profile as the first oral TYK2 inhibitor approved for adult patients with moderate to severe plaque psoriasis who are eligible for systemic therapy or phototherapy treatment.

Keyphrases

high intensity
coronary artery disease
drug administration
early onset
drug induced
stem cells
replacement therapy